Q-omics provides the consensus-scored GARS1-DT profile across patient tissues and cancer cell-line models. GARS1-DT expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GARS1-DT is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, GARS1-DT RNA expression shows 20,063 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where GARS1-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GARS1-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GARS1-DT survival associations across molecular data types. GARS1-DT RNA expression shows survival associations in the most cancer types (28), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GARS1-DT RNA expression–survival associations across cancer types. High GARS1-DT expression shows unfavorable associations in KIRC, KICH, COAD, CESC and LGG, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GARS1-DT RNA expression.
This table summarizes GARS1-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GARS1-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GARS1-DT shows lower tumor expression in BRCA and higher tumor expression in HNSC, KIRC, LIHC, KIRP and COAD. The HNSC box plot shows higher GARS1-DT RNA expression in tumor versus normal tissue (log2 FC = +0.581, t-test p < 0.001).
This table shows molecular features associated with GARS1-DT in patient tissues and cancer cell lines. In patient samples, GARS1-DT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
